Vaccine Safety Registry
Mpox Vaccine Safety
Institutional safety information on Mpox (JYNNEOS) vaccines. Clinical safety data, side effects, risk-based eligibility, and monitoring protocols from CDC and WHO sources.
Written by
Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases)
View Clinical ProfileMedically reviewed by
Dr. Rohan Gupta, MBBS, MD (Dermatology, Venereology & Leprosy)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Mpox is a viral zoonotic pathology induced by the Mpox virus, an orthopoxvirus. Transmission occurs through direct contact with infectious lesions, scabs, or systemic body fluids.
Clinical presentation typically includes a progressive rash that evolves through several stages. While statistically rare, severe systemic complications can occur, necessitating high-authority immunization protocols for high-risk cohorts.
Vaccine Formulations
Module specifics & formulations
Formulation Node
JYNNEOS
Bavarian Nordic | Orthopoxvirus Protocol
- Formulation: Live, non-replicating viral node technology.
- Authorization: Approved for individuals 18 years and older.
- Dual-protection: Provides cross-protective immunity against smallpox.
- Dosing logic: 2-dose series, administered 4 weeks apart.
Clinical Triage
Eligibility & contraindications
Primary Risk Cohorts
- Documented Mpox exposure
- High-probability exposure risk
- Orthopoxvirus laboratory personnel
Clinical Risk Factors
- Close contact with symptomatic cases
- HCPs in acute Mpox care settings
- Active regional outbreak zones
Absolute & Relative Contraindications
- Anaphylaxis to previous JYNNEOS dose
- Acute febrile illness state
- Gestational/lactation status requires shared decision-making
Adverse Events
Reported reactions & surveillance
Local Reactions
- Injection site pain/erythema
- Localized induration
- Pruritus (Itching) at site
Systemic Profile
- Generalized fatigue
- Cephalalgia (Headache)
- Myalgia
- Nausea
Surveillance Analytics
Post-market surveillance metrics
2022
Crisis Validation
Millions
Doses Synchronized
High
Trial Efficacy
Institutional Surveillance
Continuous monitoring through VAERS and 2022 outbreak response data has established JYNNEOS as a safe protocol for individuals with immunocompromised profiles.
Editorial Governance
Clinical Reviewers & Authors
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Use of JYNNEOS Vaccine for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the ACIP
MMWR Morbidity and Mortality Weekly Report, 71(22):734-742
- 2WHO2024Mpox (monkeypox) vaccination guidance: interim guidance
World Health Organization Technical Guidance Series
- 3FDA2024JYNNEOS (Smallpox and Mpox Vaccine, Live, Non-Replicating) Package Insert & Safety Data
U.S. Food and Drug Administration CBER, Bavarian Nordic
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Simran Kohli and clinically reviewed by Dr. Rohan Gupta, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.